Coverage of Psychedelics.
-
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data
2025 Jul 01, 9:28am | 777Read More...Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant...
-
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
2025 May 24, 4:11pm | 654Read More...Matthew Zorn, an attorney known for suing the federal government over cannabis and psychedelics policy, is now joining it. Zorn has been appointed Deputy General Counsel at the U.S. Department of Health and Human Services (HHS) under Secretary Robert F. Kennedy Jr., with a focus on psychedelics...
